ORIGINAL RESEARCH article
Front. Pharmacol.
Sec. Drug Metabolism and Transport
Volume 16 - 2025 | doi: 10.3389/fphar.2025.1622249
This article is part of the Research TopicAdvancements and Strategies in Predicting and Managing Clinical Drug-Drug InteractionsView all 5 articles
Safety, tolerability, and pharmacokinetics of faldaprevir after single rising doses in healthy subjects
Provisionally accepted- 1Boehringer Ingelheim pharmaceuticals, Ridgefield, United States
- 2Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Faldaprevir (FDV) is a novel NS3/NS4A inhibitor being developed for the treatment of hepatitis C infection in an interferon-free regimen. This study evaluated the safety, tolerability and pharmacokinetics of FDV following a single dose in healthy male subjects and assessed the effect of food on FDV bioavailability. Part 1: in this placebo-controlled, randomized, single-blind, single-rising-dose part of the study, 64 healthy male subjects were randomized to receive FDV in PEG/TRIS/meglumine solution at one of 8 dose levels (4–1200 mg, n=6 per dose group) or placebo (n=2 per dose group). Part 2: the effect of food on the relative bioavailability (rBA) of FDV 480 mg in solution was evaluated in an open-label, crossover comparison, with and without a high-fat breakfast, in further 10 subjects (8 FDV, 2 placebo). Following single doses of 4–1200 mg FDV, geometric mean (gMean) Cmax and AUC0-inf were 3.57–16500 ng/mL and 254–402000 h*ng/mL respectively, displaying more than dose-proportional increases in exposure. FDV was slowly absorbed with gMean t1/2 and median tmax of 15.5–39.2 hours and 4.0–14.0 hours respectively; both were dose dependent. The urinary excretion of FDV was less than 0.1% of the dose. A high fat breakfast increased systemic exposure to FDV in solution by 14%. FDV was generally well tolerated; subjects who experienced an adverse event (AE) recovered without sequelae and no serious AEs were reported. Indirect bilirubin of >3.0 mg/dL was observed in 2 subjects at 480 mg and 5 subjects at 1200 mg. In conclusion, at single doses of 4 to 1200 mg in healthy male subjects, FDV showed dose-dependent pharmacokinetics and was generally safe and well tolerated. Food had no clinically relevant effect on the rBA of FDV.
Keywords: Faldaprevir, pharmacokinetics, HCV, NS3/4A, OATP 1B
Received: 15 Jul 2025; Accepted: 20 Aug 2025.
Copyright: © 2025 Yong, Sennewald, Nehmiz, Quinson and Huang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Fenglei Huang, Boehringer Ingelheim pharmaceuticals, Ridgefield, United States
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.